Human-tissue allografts remain associated with two major problems, however. First, such allografts can be associated with the risks of bacterium and virus transmission. [5] [6] [7] 9, 14 Although the selection of a donor for tissue grafting is very rigorous, Deijkers, et al., 11 have demonstrated that organisms of low pathogenicity (mainly skin commensal organisms) can be cultured from graft material containing 50% tissue, whereas organisms of high pathogenicity (mainly contaminants from the gastrointestinal tract) can be cultured from graft material containing only 3% tissue. Lelie and colleagues 21 have estimated that the risk of virus transmission was 10-fold higher in cases of organ tissue transplantation than in those of blood transfusion. Hence, the most important preoccupation among administrators of tissue banks, in the last decade has been the reduction of this risk. Second, clinical studies have shown that allograft tissue reconstructions tend to heal slower than repairs made using autograft tissue. Minami and associates 25, 26 found that the cells of tendon tissue are antigenic. Pinkowski and colleagues 32, 33 also have demonstrated that major histocompatibility antigens or human leukocyte antigens on the cell surface are strongly immunogenic, whereas antigens present in the extracellular matrix and collagen are weakly immunogenic.
To avoid previously encountered complications, we have developed a procedure in which a sequence of multiple chemical and physical treatments are conducted to reduce the immunogenicity of the graft material as well as the risk of agent transmission. We have previously demonstrated that this treatment does not alter the biological and mechanical properties that are essential for an ideal dura mater substitute (Fig. 1) . 13 Biocompatibility testing was used to evaluate the ability of the graft to be recolonized. The cell culture response on exposure to human allografts was estimated using indirect and direct methods. Major aspects of cell physiology, such as growth, metabolic activity (succinate dehydrogenase activity), membrane integrity (neutral red uptake), and absence of cell necrosis (lactate dehydrogenase activity in the culture medium), were investigated af-ter contact between cells and extracts of grafts. Epifluorescence microscopy, which was used to study the direct contact between cells and graft, has revealed that there is good adhesion between them and spreading of human skin fibroblastic cells on the fascia lata.
This retrospective study is the first to demonstrate that fascia lata can be subjected to strong physical and chemical treatment and remain compatible with human application.
Clinical Material and Methods

Preparation of Human Tissue Allografts
The fabrication of this treated fascia lata has already been described. 13 Portions of fascia lata from selected donors were procured according to the common standards of the European Association of Muskulo Skeletal Transplantation (Vienna, 1997). Donors were selected based on a review of their medical histories, including risk factors for subacute spongiform encephalopathies. Minimum serological testing, which included detection of HIV-1 and -2, human T-cell lymphotrophic virus, hepatitis B and C, and syphilis, was performed. Procurement of the tissue was accomplished in an operating room. All instruments and equipment used for procurement were sterilized. The fascia lata was washed in sterile physiological saline solution at room temperature before shipment to the tissue bank. There, the fascia lata was mechanically stripped of its external loose connective tissue, including adipose tissue, vessels, and nerves. The remaining tissue was cut into pieces and washed by pulse lavage. The chemical treatment plan developed by the University Tissue Bank included multiple steps. Briefly, pieces of tissue were extensively defatted in absolute acetone followed by immersion in ethanol. Next, prion inactivation was obtained by applying NaOH (1 N) at room temperature for 1 hour as recommended by the World Health Organization. 40 A reduction in the immunogenicity of the tissue was obtained by protein coagulation, nuclear acid precipitation, and cell membrane degradation, which was accomplished using NaCl and H 2 O 2 . After each procedure, pieces of fascia lata were intensively washed using a continuous flow of distilled water. Allografts were freezedried, packed in a double-plastic bag, and sterilized by gamma irradiation at 25,000 Gy (IBA Mediris, Fleurus, Belgium). The allografts were then stored at room temperature (Fig. 2 ). This treatment led to the inactivation of viruses such as HIV and hepatitis B and C, and diminished bacterial activity.
2,16,35
Clinical Studies
The clinical use of the processed fascia lata in neurosur-
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Clinical application of processed dura mater substitute 1199 FIG. 1. Photomicrographs of fascia lata after the chemical and physical treatments. A: Chemical treatment destroys the cells by protein coagulation, nuclear acid precipitation, and membrane degradation, and leads to a low antigenic tissue. Goldner trichrome, original magnification ϫ 250. B: Ultrastructural analysis of the tissue performed using confocal laser scanning microscopy shows well-aligned collagen bundles (arrow) and cavities between the fibers for cell recolonization. This demonstrates that the treated fascia lata can be considered an appropriate scaffold for cell growth. Acriflavine, bar = 50 m.
FIG. 2.
Photograph of a flat freeze-dried treated human fascia lata allograft, which has been sealed in a double-plastic bag and sterilized with gamma rays. gical procedures was approved by the Committee of Medical Ethics, University Clinical Hospital and Faculty of Medicine.
The fascia lata was only used in scheduled operations. Patients with acute infection and those in poor overall health were excluded from participating in this study, as were pregnant or breast-feeding women. Before its use, the fascia lata was immersed for 5 minutes in a physiological solution to recover its flexibility. At the time of implantation, the fascia lata was trimmed and closed by suture (eight cases), glue (seven cases), or cupping (two cases). Bioadhesive agents such as fibrin glue were applied over the suture in three cases.
Postoperatively, a wound inspection and hematological examination were routinely and carefully performed. Computerized tomography scanning or magnetic resonance imaging was performed in 13 patients.
Patient Population
Between January 2000 and September 2000, 17 patients (nine male and eight female patients) ranging in age from 2 to 71 years (mean 44 years) underwent surgery to treat nine brain tumors, three cerebral malformations, three instances of trigeminal neuralgia, and two posttraumatic lesions. Follow-up periods in this trial ranged from 21 to 29 months (23.8 Ϯ 2.2 months [mean Ϯ standard deviation]) (Table 1).
Results
Complications of the Grafting Procedure
No tear was reported when the fascia lata was grafted.
Postoperatively, no wound infection and no subcutaneous cerebrospinal fluid collection were reported.
The results of the hematological examinations are reported in Fig. 3 . In nine patients a significant transient increase in the level of CRP was correlated in three cases with an increase in the number of white blood cells 1 week after the operation. In three patients, a slight increase in the CRP level was observed 1 month following the intervention. No other clinical signs or biological parameters (such as CRP level or results of a urinary analysis) of infection or inflammation were observed.
Seven patients displayed complications (for example, slight hypacusus, headache, and hemiparesia) after surgical intervention or radiotherapy. None of these complications was related to the fascia lata graft.
Postoperative computerized tomography or magnetic resonance images obtained in 13 patients revealed no abnormal findings at the site of the fascia lata implantation.
In no case was the fascia lata graft removed during a neurosurgical procedure in the follow-up period; however, 1 year after implantation, in one case the graft was removed during orthopedic surgery. In that case the treated graft had been placed in a spinal location following resection of herniated discs at L4-5. During surgery the graft was found to have been replaced by autologous tissue and there was only minimal adhesion to the underlying surface. Histological examination revealed duralike tissue composed of banded collagen, fibroblasts, and vessels (Fig. 4) .
Discussion
A dural substitute should satisfy the following criteria: 1) be unable to induce a harmful foreign body reaction; 2) be * AVM = arteriovenous malformation; CSF = cerebrospinal fluid; F = frontal; GBM = glioblastoma multiforme; O = occipital; RM = retromastoid; S = spinal; T = temporal; TP = temporoparietal; ϩ = present; Ϫ = absent.
free from any potential risk of known and unknown infections; 3) be capable of being recolonized by host tissue; 4) have mechanical properties similar to those of the natural dura mater, especially in flexibility and strength; and 5) be storable and readily available when needed. 41 To date, no material has met all these criteria. The use of many nonabsorbable materials for artificial dural grafts, such as silicone, has demonstrated that foreign body reactions persist for a long time, leading to serious complications such as intracapsular hemorrhage from excessive neovasularization. 1, 8, [27] [28] [29] 34 Due to their mechanical incompatibility and inadequate degradation rate, bioabsorbable artificial dura mater materials have not been widely used in clinical practice. The use of human dura mater grafts has been rejected by neurosurgeons because of the risk of prion (Creutzfeldt-Jakob disease) transmission. 19, 24, 37 Although Type I bovine collagen has demonstrated good cell attachment, it remains associated with the risk of bovine spongiform encephalopathy transmission.
23,39
Advantages of the Treated Fascia Lata
The risks of virus, bacterium, and prion transmission associated with this treated graft remain very low because of the rigorous control used in the selection of donors and the treatment applied, which inactivates bacteria and viruses. Sodium hydroxide and ethanol, which are included in our treatment of the graft material, have been proved to inactivate viruses. 16, 35 Gamma irradiation at a level of 25,000 Gy, which is applied to the fascia lata, has also been shown to inactivate HIV and hepatitis C. 6, 10, 17, 20, 36 The use of solvent detergents and gamma irradiation has been demonstrated to provide a significant reduction in bacterial activity. 2, 18, 20, 22 Because prion inactivation should become a priority for allografts, we applied NaOH (1 N) to the fascia lata following the recommendation given by the World Health Organization in 1992. 3, 4, 12, 40 At the end of our treatment, the fascia lata allograft presents no risk of conventional or nonconventional agent transmission.
This graft is a bioabsorbable composite sheet composed of well-aligned collagen bundles and cavities between the fibers for cell recolonization of the matrix (Fig. 1) . Indeed, an in vitro study has already demonstrated that the treated graft is a fully biocompatible graft and an appropriate scaffold for cell recolonization. 13 Our clinical study has shown that treated grafts do not induce an inflammatory reaction or a reaction caused by a lack of matrix recolonization. We have demonstrated that the treated fascia lata is replaced by autologous collagenous tissue. Use of this graft can minimize the potential risk of chronic foreign body reaction against nonabsorbable synthetic material.
The use of treated human fascia lata allografts in various cranial and spinal locations has proved this material to be a successful substitute for dura mater, with respect to its flexibility and performance. Its storage capacity and its availability in various sizes in our tissue bank has allowed surgeons to choose the most suitable graft for a specific surgical indication. Its use has proved to be advantageous. 30 This graft material also has been used in orthopedic (for synostosis and to accomplish tenodesis), abdominal, and otorhinolaryngological surgical procedures. To date, the graft has been used in 33 cases for purposes other than as a dural substitute.
Conclusions
Our chemically and physically treated human fascia lata graft material has satisfied all the criteria required for a dural substitute and is, therefore, a good alternative in cases of elective surgery or repeated operations.
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